Table 1.
Patient and tumor characteristics for the three subgroups (N = 139).
| Patients | Primary surgery subgroup, N = 50 | Primary surgery + adjuvant oncology subgroup, N = 22 | Primary oncology subgroup, N = 67 |
|---|---|---|---|
| Age (mean ± SD) | 45.7 ± 12.0 | 48.6 ± 13.3 | 54.8 ± 15.7 |
| Histology | n (%) | n (%) | n (%) |
| SCC | 29 (58) | 15 (68.2) | 62 (92.5) |
| AC | 16 (32.0) | 5 (22.7) | 5 (7.5) |
| ASC | 5 (10.0) | 2 (9.1) | 0 (0.0) |
| FIGO 2018 a | n (%) | n (%) | n (%) |
| IA1 | 1 (2.0) | 0 (0.0) | 0 (0.0) |
| IA2 | 15 (30.0) | 0 (0.0) | 0 (0.0) |
| IB1 | 16 (32.0) | 0 (0.0) | 0 (0.0) |
| IB2 | 16 (32.0) | 9 (40.9) | 0 (0.0) |
| IB3 | 2 (4.0) | 1 (4.5) | 3 (4.5) |
| IIA1 | 0 (0.0) | 2 (9.1) | 0 (0.0) |
| IIB | 0 (0.0) | 0 (0.0) | 26 (38.8) |
| IIIB | 0 (0.0) | 0 (0.0) | 1 (1.5) |
| IIIC1 | 0 (0.0) | 0 (40.9) | 32 (47.8) |
| IIIC2 | 0 (0.0) | 1 (4.5) | 3 (4.5) |
| IVA | 0 (0.0) | 0 (0.0) | 2 (3.0) |
| T‐score (mean ± SD) b | 1.1 ± 0.7 | 2.2 ± 0.4 | 5.9 ± 3.1 |
| Tumor size (mm) (mean ± SD) c | 17.2 ± 9.1 | 27.4 ± 7.6 | 52.3 ± 20.8 |
| HPV genotype tissue d | n (%) | n (%) | n (%) |
| 16 | 23 (46.0) | 7 (31.8) | 37 (55.2) |
| 18 | 11 (22.0) | 5 (22.7) | 6 (9.0) |
| 31 | 2 (4.0) | 1 (4.5) | 3 (4.5) |
| 33 | 1 (2.0) | 2 (9.1) | 4 (6.0) |
| 45 | 5 (10.0) | 2 (9.1) | 7 (10.4) |
| Other | 3 (6.0) | 3 (13.6) | 5 (7.5) |
| Multiple | 5 (10.0) | 2 (9.1) | 5 (7.5) |
Disease stage according to FIGO 2018 [2]. For patients having been re‐staged after surgery, the re‐staged stage is the one listed. For primary stage, see Table S1.
T‐score according to Lindegaard et al. [55]. The scoring system is developed for CC patients with stage IB‐IVB disease, giving patients with stage IB1, IB2, and IB3 a T‐score of 1, 2, and 3 respectively. Thus, for patients with stage IA1 and IA2 disease, we made a presumption that stage IA1 equals a T‐score of 0.25 and stage IA2 equals a T‐score of 0.5. For early‐stage patients having been re‐staged after surgery, the re‐staged stage is the one used to determine T‐score. For primary disease stage, see Table S1.
Large diameter of tumor. For the primary surgery subgroup and the primary surgery + adjuvant oncology subgroup, tumor size was evaluated pathologically after surgery based on the removed tissue. For the primary oncology subgroup, tumor size was evaluated based on clinical examination or magnetic resonance imaging (MRI) prior to treatment.
Cervical tissue samples tested with the HPV NGS genotyping panel.